Clinical Trials Using Atezolizumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Atezolizumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 112

  • Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery

    This phase IIa trial studies the side effects of atezolizumab when given together with paclitaxel, trastuzumab, and pertuzumab and to see how well it works in treating patients with HER2 positive breast cancer that has come back at or near the same place as the original (primary) tumor (locally recurrent), has spread to other places in the body (metastatic), or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trastuzumab is a form of targeted therapy because it works by attaching itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Pertuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, paclitaxel, trastuzumab, and pertuzumab may work better in treating patients with HER2 positive breast cancer.
    Location: 3 locations

  • Atezolizumab, Entinostat, and Bevacizumab in Treating Patients with Metastatic Kidney Cancer

    This phase I / II trial studies the side effects and best dose of entinostat when given together with atezolizumab and bevacizumab and how well they work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, entinostat, and bevacizumab may work better in treating patients with kidney cancer.
    Location: 3 locations

  • Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects

    This study will evaluate SYNB1891 (investigational product) administered as intratumoral injections in subjects diagnosed with advanced / metastatic solid tumors and lymphoma for possible treatment. Eligible subjects will receive SYNB1891 intratumorally and will undergo imaging to assess tumor response, safety monitoring and subsequent follow-up after investigational product (IP) administration. Once dose limiting toxicity (DLT) for SYNB1891 is determined, it will be administered at one log dose level lower in combination with atezolizumab.
    Location: 3 locations

  • A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

    This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected or ablated hepatocellular carcinoma (HCC) who are at high risk for disease recurrence.
    Location: 4 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • Atezolizumab and Chemotherapy in Treating Patients with Metastatic or Unresectable and Locally Advanced Urothelial Carcinoma

    This phase II trial studies how well atezolizumab and chemotherapy work in treating patients with urothelial carcinoma that has spread to other places in the body or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin, gemcitabine hydrochloride, and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab and chemotherapy may work better in treating patients with urothelial carcinoma.
    Location: 2 locations

  • A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer

    This study (also known as IMpassion050) will evaluate the efficacy and safety of atezolizumab compared with placebo when given in combination with neoadjuvant dose-dense anthracycline (doxorubicin) + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab (ddAC-PacHP) in patients with early HER2-positive breast cancer (T2-4, N1-3, M0).
    Location: 2 locations

  • Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical, Vaginal, or Vulvar Cancer

    This phase II trial studies how well stereotactic body radiation therapy (SBRT) and atezolizumab works in treating patients with cervical, vaginal, or vulvar cancer that has come back (recurrent), does not go to remission despite treatment (persistent), or has spread to other places in the body (metastatic). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SBRT and atezolizumab may work better in treating patients with cervical, vaginal, or vulvar cancer.
    Location: 2 locations

  • A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline / Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

    This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
    Location: 2 locations

  • Atezolizumab and Stereotactic Radiation in Treating Participants with Stage IV Triple Negative Breast Cancer and Brain Metastasis

    This phase II trial studies how well atezolizumab and stereotactic radiosurgery work in treating participants with stage IV triple negative breast cancer that has spread to the brain. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic radiation is a specialized radiation therapy that uses many precisely focused radiation beams to treat tumors with minimal impact on the surrounding healthy tissue. Giving atezolizumab and stereotactic radiation may work better in treating participant with triple negative breast cancer.
    Location: 2 locations

  • Atezolizumab in Combination with Carboplatin and Paclitaxel before Surgery in Treating Participants with Newly-Diagnosed Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    This phase I trial studies the side effects of atezolizumab in combination with carboplatin and paclitaxel before surgery in treating participants with newly-diagnosed stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with carboplatin and paclitaxel before surgery may work better in treating participants with ovarian, fallopian tube, or primary peritoneal cancer.
    Location: 2 locations

  • A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

    This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in patients with metastatic non-small cell lung cancer (NSCLC). Two cohorts will be enrolled in parallel in this study: the first-line (1L) cohort will consist of patients who have not received any systemic therapy for their disease and the second-line (2L) cohort will consist of patients who progressed during or after receiving a platinum-containing regimen and a PD-L1 / PD-1 checkpoint inhibitor treatment. In each cohort, eligible patients will be assigned to one of several treatment arms.
    Location: 2 locations

  • Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer

    This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • Atezolizumab in Treating Patients with Non-metastatic Bladder Cancer

    This phase II trial studies the best dose of atezolizumab and how well it works in treating patients with bladder cancer that has not spread to other places in the body. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 3 locations

  • Intermittent Checkpoint Inhibitor Therapy for the Treatment of Advanced or Metastatic Urothelial Cancer

    This phase II trial studies how well intermittent checkpoint inhibitor therapy works in treating patients with urothelial cancer that has spread to other places in the body (advanced or metastatic). Checkpoint inhibitors, such as pembrolizumab, atezolizumab, durvalumab, nivolumab, and avelumab, are drugs that work by helping the immune system recognize and kill cancer cells. This study is being done to find out whether intermittent checkpoint inhibitor therapy works the same, better, or worse than continued checkpoint inhibitor therapy in treating patients with urothelial cancer.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

    This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • D2C7-IT and Atezolizumab for the Treatment of Recurrent Glioblastoma

    This phase I trial studies the side effects of D2C7-immunotoxin (IT) when given together with atezolizumab in treating patients with glioblastoma that has come back (recurrent). An immunotoxin is a human-made protein that consists of a targeting portion linked to a toxin. The toxin is based on a portion of a common bacteria that the immune system cells will recognize. D2C7-IT is engineered to recognize two receptors, epidermal growth factor wild type (EGFRwt) and epidermal growth factor variant type III (EGFR-vIII). These receptors are expressed in many glioblastoma cells. Atezolizumab is a monoclonal antibody that unblocks “checkpoint” proteins that interfere with the immune system attacking tumor cells. Combining D2C7-IT with a checkpoint inhibitor, such as atezolizumab, may be effective against glioblastoma.
    Location: Duke University Medical Center, Durham, North Carolina

  • Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

    This phase III trial compares 1 year immunotherapy treatment versus continuous immunotherapy treatment beyond 1 year in patients with solid tumors that have spread to other places in the body (advanced). Immunotherapy such as pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are drugs given through a vein to the entire body to activate the immune system. Comparing the treatment lengths may help doctors determine the ideal length of time for treatment with immunotherapy in patients with solid tumors.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Immunotherapy (Atezolizumab and Varlilumab) in Combination with Radiation Therapy for the Treatment of Advanced Unresectable Non-small Cell Lung Cancer

    This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies such as atezolizumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies such as varlilumab may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving atezolizumab, varlilumab, and radiation therapy may increase the amount of time the disease is not active or does not spread to another part of the body.
    Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

  • Derazantinib and Atezolizumab in Patients With Urothelial Cancer

    The purpose of this study is to evaluate efficacy of derazantinib single-agent or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.
    Location: Yale University, New Haven, Connecticut

  • Immunotherapy (Atezolizumab) and Vaccines (MVA-BN-Brachyury and PROSTVAC) for the Treatment of Intermediate-Risk and High-Risk Localized Prostate Cancer, the AtezoVax Study

    This trial studies how well atezolizumab, MVA-BN-brachyury and PROSTVAC work for the treatment of intermediate-risk and high-risk localized prostate cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PROSTVAC includes the use of two doses; a prime vaccine, PROSTVAC-V (the first vaccine may generate a response from the immune system) and a boost vaccine, PROSTVAC-F (the second vaccine may increase and maintain the response of the immune system). The MVA-BN-brachyury vaccine used with the PROSTVAC vaccine may start an immune response in the tumor. An ‘immune response’ is the process of the body detecting and attacking foreign bodies such as cancer cells. Immune responses are effective in killing some forms of cancer. Giving atezolizumab, MVA-BN-brachyury and PROSTVAC may work better than MVA-BN-brachyury and PROSTVAC alone.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Atezolizumab with or without PEGPH20 before and after Surgery for the Treatment of Stage I-II Resectable Pancreatic Cancer

    This phase II trial studies how well atezolizumab with or without PEGPH20 given before and after surgery works in treating patients with stage I-II pancreatic cancer that can be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. PEGPH20 may stop the growth of tumor cells by breaking down hyaluronan, a tissue component needed for cell growth. Giving atezolizumab with PEGPH20 before and after surgery may increase immune response compared to atezolizumab alone.
    Location: NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center, New York, New York

  • Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

    MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).
    Location: 3 locations

  • A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy

    A Phase Ib / II, open-label, multicenter, randomized, umbrella study in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status).
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Ipatasertib in Combination with Carboplatin, Carboplatin / Paclitaxel, or Capecitabine / Atezolizumab in Treating Patients with Metastatic Triple Negative Breast Cancer

    This phase I trial studies best dose of ipatasertib and how well it works with carboplatin with or without paclitaxel in treating patients with triple negative breast cancer that has spread to other places in the body (metastatic). Ipatasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving ipatasertib in combination with carboplatin, carboplatin / paclitaxel, or capecitabine / atezolizumab will work better in treating patients with triple negative breast cancer.
    Location: City of Hope Comprehensive Cancer Center, Duarte, California